NCT01466972View on ClinicalTrials.gov

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

April 27, 2012

Primary Completion Date

December 7, 2015

Study Completion Date

October 2, 2019

Conditions

Breast CancerBreast Neoplasm

Interventions

DRUG

Pazopanib

Oral, 800mg tablet daily per cycle

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Hope Rugo, MD

OTHER

NCT01466972 - Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib | Biotech Hunter | Biotech Hunter